New 30-month survival data from the CheckMate 214 study were presented at the American Society for Clinical Oncology (ASCO) genitourinary (GU) conference in San Francisco in February 2019.
Additional 30-month follow-up data from the phase 3 CheckMate 214 trial confirms the survival benefit of the nivolumab plus ipilimumab combination over sunitinib as a first-line treatment for patients with intermediate- and poor-risk advanced renal cell carcinoma (RCC).
Previously reported data followed the patients for 18 months. In this new analysis, presented by Dr Nizar Tannir of the University of Texas MD Anderson Cancer Center in Houston, patients with intermediate- and poor-risk advanced RCC treated with the nivolumab plus ipilimumab combination had a significant 34% decreased risk of death compared with sunitinib-treated patients. In addition, the overall survival rate at 24 months (66% vs 53%) and the objective response rate (42% vs 29%) were significantly higher for patients treated with combination compared to those treated with sunitinib monotherapy. Progression-free survival at 24 months was 30% in the nivolumab-ipilimumab group compared with 17% in the sunitinib group.